Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

386 results about "Eating disorders" patented technology

A condition characterized by irregular or abnormal eating habits.

Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto

Disclosed are devices and methods for detecting, preventing, and / or treating neurological disorders. These devices and methods utilize electrical stimulation, and comprise a unique concentric ring electrode component. The disclosed methods involve the positioning of multiple electrodes on the scalp of a mammal; monitoring the mammal's brain electrical patterns to identify the onset of a neurological event; identifying the location of the brain electrical patterns indicative of neurological event; and applying transcutaneous or transcranial electrical stimulation to the location of the neurological event to beneficially modify brain electrical patterns. The disclosed methods may be useful in the detection, prevention, and / or treatment of a variety of indications, such as epilepsy, Parkinson's Disease, Huntington's disease, Alzheimer's disease, depression, bipolar disorder, phobia, schizophrenia, multiple personality disorder, migraine or headache, concussion, attention deficit hyperactivity disorder, eating disorder, substance abuse, and anxiety. The disclosed methods may also be used in combination with other peripheral stimulation techniques.
Owner:LOUISIANA TECH UNIV RES FOUND A DIV OF LOUISIANA TECH UNIV FOUND +1

System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities

A system and method for providing pulsed electrical stimulation to one or both vagus nerve(s) of a patient to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders. The electrical pulses can be provided either unilaterally or bilaterally (left and right vagus nerves) and can be supra-diaphramatic or be sub-diaphramatic. The system comprising implantable stimulator, lead(s), an external stimulator, and a programmer. The implantable stimulator, comprising a pulse generator module, and a stimulus-receiver module which is used in conjunction with an external stimulator. Control circuitry ensures selective operation of one of the modules of the implanted stimulator, at a time. Further, the external stimulator comprises a telemetry module for remotely activating (or de-activating) programs over the internet, to arrive at the optimal program for each patient. Once the optimal “dose” is titrated using the external stimulator, the implanted pulse generator can then be programmed to similar parameters. The external stimulator in conjunction with the implanted stimulus-receiver can override the implanted pulse generator module, to provide extra dose of therapy, and also to conserve the implanted battery. The external stimulator is networked to other computers. Using the networking, a physician situated remotely can monitor and program the devices, as well as, automatically generate invoicing. In one embodiment, the external stimulator also comprises GPS circuitry for locating patient.
Owner:NEURO & CARDIAC TECH

External pulse generator for adjunct (add-on) treatment of obesity, eating disorders, neurological, neuropsychiatric, and urological disorders

An external pulse generator comprising a primary coil and adapted to inductively couple to an implanted receiving means, is designed to deliver neuromodulation therapy for disorders comprising obesity, eating disorders, anxiety and the like. The external pulse generator contains limited number of predetermined programs. These programs provide the patient or caretaker a means to adjust the therapy within confined limits, or turn the device off. The predetermined programs contain unique combination of pulse amplitude, pulse width, frequency of stimulation, and on-off time. In another mode of operation, the parameters can be individually adjusted and the stimulation therapy program can be “customized” for the patient, and stored in the memory. The programs are capable of being modified with a programming station connected to the pulse generator with a RS232-C serial connection. Additionally, the external pulse generator has two-way wireless capabilities, whereby enabling the physicians to remotely control the therapy programs of their patients using wireless internet. Moreover, the external pulse generator has proximity sensing and feedback regulation component to provide a constant therapy in accordance with the predetermined programs.
Owner:NEURO & CARDIAC TECH

Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds

This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (+) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.
Owner:SEPACOR INC

Use of exendins for the reduction of food intake

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:ASTRAZENECA PHARMA LP

Noninvasively adjustable gastric band

ActiveUS20060247722A1ElectrotherapyObesity treatmentLower esophagusFeeding disability
A method and apparatus for treatment of an eating disorder includes electrically, mechanically and / or pharmaceutically / chemically stimulating a of the vagus nerve of the lower esophagus, cardia, esophageal / cardia junction, cardia / fundus junction or upper stomach so as to induce afferent action potentials on the vagus nerve. The device may be noninvasively adjusted after implantation to provide increased or decreased restriction on the patient's gastrointestinal tract. Each stimulus may be administered as a series of programmed pulses of defined amplitude, duration and period, to evoke a responsive signal to the brain by the target nerve, effective for producing a temporary feeling of satiety in the person. An implantable stimulus generator may be operatively coupled to a nerve electrode, pressure device or chemical outlet to apply a defined signal to a selected nerve branch. The implantable stimulus generator is programmable to allow clinician programming of defined signal parameters effective to treat the eating disorder of the patient. Methods are also provided to identify electrodes nearest to a branch of the vagus nerve to apply an electrical stimulation signal with improved efficiency.
Owner:CYBERONICS INC

Methods for treating gastrointestinal disorders

InactiveUS20060036293A1Decrease muscle activityAvoid the needElectrotherapyDiseaseSphincter
A small implantable stimulator(s) having at least two electrodes is implanted adjacent to a gastrointestinal nerve and / or muscle for the stimulation treatment of gastrointestinal disorders, including gastrointestinal motility, sphincteric disorders, and / or eating disorders. The stimulator provides a means of stimulating tissue at a stimulation site when desired, and may be implanted via a minimal surgical procedure.
Owner:BOSTON SCI NEUROMODULATION CORP

Gastro-occlusive device

InactiveUS20050267405A1SurgeryDilatorsOcclusiveStomach walls
A gastro-occlusive device, comprising a balloon disposable in a stomach cavity of a patient, and inflatable therein to occlude a portion of the volume of the stomach cavity, a gas flow tube coupled at a distal end thereof with the balloon and extending outwardly through a stomach wall for coupling with a gas source for selectively inflating the balloon, to occlude at least a portion of the volume of the stomach cavity. The gastro-occlusive device may be employed in combination with a feeding tube unit, a drain unit or other ancillary apparatus, and is useful for treatment of morbid obesity and various eating disorders.
Owner:POLYZEN INC

Obesity and eating disorder stimulation treatment with neural block

A method and apparatus for treating patients suffering from obesity or eating disorders by applying a predetermined stimulating signal to the patient's vagus nerve appropriate to alleviate the condition and by applying a neural conduction block to the vagus nerve at a blocking site with the neural conduction block selected to at least partially block nerve impulses on the vagus nerve at the blocking site.
Owner:RESHAPE LIFESCIENCES INC

Identification of electrodes for nerve stimulation in the treatment of eating disorders

ActiveUS20060247721A1ElectrotherapyObesity treatmentLower esophagusFeeding disability
A method and apparatus for treatment of an eating disorder includes electrically, mechanically and / or pharmaceutically / chemically stimulating a of the vagus nerve of the lower esophagus, cardia, esophageal / cardia junction, cardia / fundus junction or upper stomach so as to induce afferent action potentials on the vagus nerve. The device may be noninvasively adjusted after implantation to provide increased or decreased restriction on the patient's gastrointestinal tract. Each stimulus may be administered as a series of programmed pulses of defined amplitude, duration and period, to evoke a responsive signal to the brain by the target nerve, effective for producing a temporary feeling of satiety in the person. An implantable stimulus generator may be operatively coupled to a nerve electrode, pressure device or chemical outlet to apply a defined signal to a selected nerve branch. The implantable stimulus generator is programmable to allow clinician programming of defined signal parameters effective to treat the eating disorder of the patient. Methods are also provided to identify electrodes nearest to a branch of the vagus nerve to apply an electrical stimulation signal with improved efficiency.
Owner:LIVANOVA USA INC

Cranial nerve stimulation to treat eating disorders

Methods and systems of treating a patient having an eating disorder involving coupling at least one electrode to at least one cranial nerve of the patient, implanting a sensory stimulation device in the patient, applying a sensory stimulus to the patient using the sensory stimulation device, detecting the patient's response to the sensory stimulus, and applying an electrical signal to the cranial nerve using the electrode after detecting the response to treat the eating disorder. The methods and systems are effective in treating bulimia.
Owner:LIVANOVA USA INC

Method and system for providing therapy for bulimia/eating disorders by providing electrical pulses to vagus nerve(s)

A method and system to provide pre-determined electrical pulses for neuromodulating vagus nerve(s) or its branches to provide therapy for bulimia / eating disorders, comprises implantable and external components. The electrical pulses to vagus nerve(s) may be stimulating and / or blocking. The pulsed electrical stimulation / blocking to vagus nerve(s) may be provided using one of the following stimulation systems, such as: a) an implanted stimulus-receiver with an external stimulator; b) an implanted stimulus-receiver comprising a high value capacitor for storing charge, used in conjunction with an external stimulator; c) a programmer-less implantable pulse generator (IPG) which is operable with a magnet; d) a microstimulator; e) a programmable implantable pulse generator; f) a combination implantable device comprising both a stimulus-receiver and a programmable implantable pulse generator (IPG); and g) an implantable pulse generator (IPG) comprising a rechargeable battery. In one embodiment, the external components such as the programmer or external stimulator may comprise a telemetry means for networking. The telemetry means therefore allows for interrogation or programming of implanted device, from a remote location over a wide area network.
Owner:NEURO & CARDIAC TECH

Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC

Method and system for providing therapy for bulimia/eating disorders by providing electrical pulses to vagus nerve(s)

A method and system to provide pre-determined electrical pulses for neuromodulating vagus nerve(s) or its branches to provide therapy for bulimia / eating disorders, comprises implantable and external components. The electrical pulses to vagus nerve(s) may be stimulating and / or blocking. The pulsed electrical stimulation / blocking to vagus nerve(s) may be provided using one of the following stimulation systems, such as: a) an implanted stimulus-receiver with an external stimulator; b) an implanted stimulus-receiver comprising a high value capacitor for storing charge, used in conjunction with an external stimulator; c) a programmer-less implantable pulse generator (IPG) which is operable with a magnet; d) a microstimulator; e) a programmable implantable pulse generator; f) a combination implantable device comprising both a stimulus-receiver and a programmable implantable pulse generator (IPG); and g) an implantable pulse generator (IPG) comprising a rechargeable battery. In one embodiment, the external components such as the programmer or external stimulator may comprise a telemetry circuit for networking. The telemetry circuit therefore allows for interrogation or programming of implanted device, from a remote location over a wide area network.
Owner:NEURO & CARDIAC TECH

Method of using spinal cord stimulation to treat gastrointestinal and/or eating disorders or conditions

ActiveUS20060074456A1Enhance gastric motilityIncreasing) gastric motilityElectrotherapyDiseaseMedicine
The present invention involves a method and a system for using electrical stimulation to treat gastrointestinal and / or eating disorders. More particularly, the method comprises surgically implanting an electrical stimulation lead that is in communication with predetermined thoracic vertebral segments to cause spinal nervous tissue stimulation, thus treating a wide variety of gastrointestinal disorders.
Owner:ADVANCED NEUROMODULATION SYST INC

4-Aminoquinoline compounds

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
Owner:DEVITA ROBERT J +5

Gip analog and hybrid polypeptides with selectable properties

ActiveUS20080312157A1Increased insulin secretionDecreasing bone loss bonePeptide/protein ingredientsMetabolism disorderDyslipidemiaFeeding disability
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP

System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities

A system and method for providing pulsed electrical stimulation to one or both vagus nerve(s) of a patient to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders. The electrical pulses can be provided either unilaterally or bilaterally (left and right vagus nerves) and can be supra-diaphramatic or be sub-diaphramatic. The system comprising implantable stimulator, lead(s), an external stimulator, and a programmer. The implantable stimulator, comprising a pulse generator module, and a stimulus-receiver module which is used in conjunction with an external stimulator. Control circuitry ensures selective operation of one of the modules of the implanted stimulator, at a time. Further, the external stimulator comprises a telemetry module for remotely activating (or de-activating) programs over the internet, to arrive at the optimal program for each patient. Once the optimal “dose” is titrated using the external stimulator, the implanted pulse generator can then be programmed to similar parameters. The external stimulator in conjunction with the implanted stimulus-receiver can override the implanted pulse generator module, to provide extra dose of therapy, and also to conserve the implanted battery. The external stimulator is networked to other computers. Using the networking, a physician situated remotely can monitor and program the devices, as well as, automatically generate invoicing. In one embodiment, the external stimulator also comprises GPS circuitry for locating patient.
Owner:NEURO & CARDIAC TECH

Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC

Dynamic nerve stimulation in combination with other eating disorder treatment modalities

InactiveUS20080262411A1Provide central nervous system satietyIncreased energy expenditureBiocideOrganic active ingredientsDiseaseWeight-loss drugs
A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.
Owner:ADVANCED NEUROMODULATION SYST INC

Gip analog and hybrid polypeptides with selectable properties

InactiveUS20090036364A1Increased insulin secretionDecreasing bone loss boneSenses disorderNervous disorderDyslipidemiaPhysiology
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP

Method and system for providing electrical pulses to gastric wall of a patient with rechargeable implantable pulse generator for treating or controlling obesity and eating disorders

Method and system for providing electrical pulses to the gastric wall of a patient to provide therapy for obesity / eating disorders comprises implantable and external components. The implantable components are a lead and rechargeable implantable pulse generator, comprising rechargeable lithium-ion or lithium-ion polymer battery. The external components are a programmer and an external recharger. In one embodiment, the implanted pulse generator may also comprise stimulus-receiver means, and a pulse generator means with rechargeable battery. The rechargeable implanted pulse generator of this embodiment is also adapted to work in conjunction with an external stimulator. In another embodiment, the implanted pulse generator is adapted to be rechargeable, utilizing inductive coupling with an external recharger. Existing gastric stimulators may also be adapted to be used with rechargeable power sources as disclosed herein. The implanted system may also use a lead with two or more electrodes, for selective stimulation and / or blocking. In another embodiment, the external stimulator and / or programmer may comprise an optional telemetry unit. The addition of the telemetry unit to the external stimulator and / or programmer provides the ability to remotely interrogate and change stimulation programs over a wide area network, as well as other networking capabilities.
Owner:BOVEJA BIRINDER R +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products